CSIRO, Black Mountain, GPO Box 1700, Acton, Canberra, Australian Capital Territory, 2601, Australia.
J Biomed Mater Res A. 2019 Aug;107(8):1763-1770. doi: 10.1002/jbm.a.36695. Epub 2019 May 1.
If tolerated in biological environments, recombinant structural proteins offer the advantage that biological cues dictating cell attachment and material degradation can be modified as required for clinical application using genetic engineering. In this study, we investigate the biological response to materials generated from the recombinant honeybee silk protein, AmelF3, a structural protein that can be produced at high levels by fermentation in Escherichia coli. The protein can be readily purified from E. coli host cell proteins after transgenic production and fabricated into various material formats. When implanted subcutaneously according to International Standard ISO 10993 tests, materials generated from the purified recombinant protein were found to be noncytotoxic, inducing a transient weak immunogenic response and a chronic inflammatory response that resolved over time. While preliminary, this study supports the ongoing development of materials generated from this protein for biomedical applications. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1763-1770, 2019.
如果重组结构蛋白在生物环境中可以耐受，那么它们具有这样的优势，即可以使用基因工程来修饰决定细胞附着和材料降解的生物信号，从而满足临床应用的要求。在这项研究中，我们研究了生物对重组蜜蜂丝蛋白 AmelF3 材料的反应，AmelF3 是一种结构蛋白，可通过大肠杆菌中的发酵大量生产。在转基因生产后，该蛋白可以很容易地从大肠杆菌宿主细胞蛋白中纯化出来，并制成各种材料形式。根据国际标准 ISO 10993 测试，当皮下植入时，从纯化的重组蛋白中生成的材料被发现无细胞毒性，引起短暂的弱免疫原性反应和慢性炎症反应，随着时间的推移而消退。虽然这只是初步研究，但它支持了该蛋白材料在生物医学应用中的持续开发。© 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A：107A：1763-1770，2019。
